Sign in

ACIR

@acir-org.bsky.social
606 followers 112 following 695 posts

Accelerating Cancer Immunotherapy Research. A free weekly digest of the latest findings in #cancer #immunotherapy. We spotlight promising research and attend major meetings. We also make cool images :)

PostsRepliesMedia
ACIR @acir-org.bsky.social · 09/10/2026
Jiang and He et al. show that during vascular migration, circulating tumor cells release antigen-enriched migrasomes, which stimulate anti-metastatic immunity. bit.ly/4em1W1J
000
ACIR @acir-org.bsky.social · 09/10/2026
Menzel, Zhou et al. observed persisting responses to ICB in melanoma patients and orthotopic tumor mouse models upon complete regional tumor-draining lymph node (LN) dissection. bit.ly/4zimpfU  @harvardmed.bsky.social
000
ACIR @acir-org.bsky.social · 08/10/2026
Using a computational strategy, Radman et al. mutated the constant and transmembrane regions of the MART-1 DMF4 TCR α/β chains to reduce mispairing and improve expression. bit.ly/3Vu61KU  @goodmanfaculty.bsky.social
000
ACIR @acir-org.bsky.social · 08/10/2026
Noblecourt and Wicki et al. showed that carboplatin and paclitaxel (CarboTaxol) with viral vector vaccines expanded antigen-specific TCF1+CD8+ T cells during priming, slowed tumor growth, and improved survival in mouse models. bit.ly/4hzGokl   @ludwigcancer.bsky.social
000
ACIR @acir-org.bsky.social · 07/10/2026
Messemaker and Kwee et al. developed a TCR rapid assembly platform (T-RAP) that could be used to evaluate TCR reactivity acir.org/weekly-dige... @schumacher-lab.bsky.social @nkinl.bsky.social
032
ACIR @acir-org.bsky.social · 06/10/2026
Malinconico et al. engineered T cells with both a CAR targeting CD176 (expressed in NSCLC and other tumors), and an inducible cassette encoding either IL-18 or IL-12 that would be expressed following CAR activation of NF-κB.   @aacrjournals.bsky.social bit.ly/4rFOStG
011
ACIR @acir-org.bsky.social · 05/10/2026
Lin et al. engineered an oncolytic herpesvirus (oHSV) with a PD-L1 nanobody attached to gD on the viral envelope surface (gDαPD- L1), targeting the virus to both tumors and TAMs expressing PD-L1. bit.ly/3VlMNHh
000
ACIR @acir-org.bsky.social · 02/10/2026
St. Paul and Hendrikse et al. used single-cell sequencing and developed a machine-learning algorithm (PreGame) to distinguish the enigmatic tumor-reactive γδ T cells (TRγδ T cells) from bystander cells and confirm their specificity.  @pmresearch-uhn.bsky.social bit.ly/4ypCkcg
000
ACIR @acir-org.bsky.social · 02/10/2026
Duzagac et al. characterized circulating neoantigen-specific T cells in Lynch syndrome (LS) carriers using functional assays, single-cell RNA/TCR sequencing, and integration with existing TCR datasets.  @mdanderson.bsky.social bit.ly/4yXP9dG
000
ACIR @acir-org.bsky.social · 01/10/2026
Hwang et al. engineered high-affinity antibodies against HLA-E–VL9 using structure-based design and high-throughput library screening to block inhibitory NKG2A/CD94 interactions.  @dukemedschool.bsky.social bit.ly/4iRh2iZ
000
ACIR @acir-org.bsky.social · 01/10/2026
Using novel Tg mouse models, Xu et al. identified a TCR specific for a clinically relevant epitope rarely expressed on CD8+ T cells in chronic HBV infection. bit.ly/4hTDYNr
120
ACIR @acir-org.bsky.social · 30/09/2026
New combination for PDAC acir.org/weekly-dige... @danafarber.bsky.social @harvardcellbio.bsky.social
001
ACIR @acir-org.bsky.social · 29/09/2026
Asano, Veatch, and Sung et al. identified TCRMCC1, a high-avidity HLA-A*02:01-restricted TCR targeting Merkel cell polyomavirus large-T antigen and treated seven patients who had ICI-refractory metastatic MCC using autologous TCRMCC1-transduced [...] @fredhutch.org bit.ly/46BEhGz
000
ACIR @acir-org.bsky.social · 28/09/2026
Using scRNA sequencing, Ng et al. compared LN biopsy samples (non-affected vs. tumor-affected) from SCLC patients to study the antitumor role of MHC-I-independent pathways. bit.ly/4rAAbrS   @wehi-research.bsky.social
000
ACIR @acir-org.bsky.social · 25/09/2026
Smith, Dao, and Gavil et al. showed that activation of unexhausted non-tumor-specific memory T cells in the TIME induced tumor clearance in the absence of NK cell- or TCRαβ-dependent tumor cell recognition, although the latter[...] bit.ly/4AsZ38H @oliviacs.bsky.social @cfi-umn.bsky.social
000
ACIR @acir-org.bsky.social · 25/09/2026
Qing and Ghorani et al. explored mechanisms of secondary resistance (2°R) to therapy (Treg depletion via anti-CD25 mAb + GM-CSF-expressing tumor cell vaccine) in B16 tumor- bearing mice.  @aacrjournals.bsky.social bit.ly/4h9JjA1
001
ACIR @acir-org.bsky.social · 24/09/2026
Haratani et al. found that most neoantigens arising from truncal mutations in TP53 were not presented, either because they arose from processing-resistant regions of p53 or because the required HLA allele was absent. bit.ly/4ArRQ91  @danafarbernews.bsky.social
000
ACIR @acir-org.bsky.social · 24/09/2026
Falcomatà et al. used perturb-map spatial functional genomics to identify tumor-derived extracellular factors that promote PDAC immune evasion. bit.ly/4yaTJ8r @chiarafalcomata.bsky.social @brownlab1.bsky.social
000
ACIR @acir-org.bsky.social · 23/09/2026
PLA2G2D, produced by a unique subset of lymph node macrophages, suppresses T cells and could be targeted for immunotherapy acir.org/weekly-dige...
000
ACIR @acir-org.bsky.social · 22/09/2026
Ibrahim et al. profiled sotorasib-induced changes in syngeneic KRASG12C/Trp53−/− lung and colon carcinoma models with and without anti-PD-1. bit.ly/4h4qUTW  @aacrjournals.bsky.social
001
ACIR @acir-org.bsky.social · 21/09/2026
Tian et al. fused second-generation CAR-macrophages with neutrophils, generating syncytial (S)-CAR-M with enhanced chemokine-driven solid tumor infiltration and cytotoxicity. bit.ly/4xZBIda
000
ACIR @acir-org.bsky.social · 18/09/2026
Golubovskaya et al. showed that intratumoral delivery of an anti-human EpCAM-CD3 BiTE mRNA-LNP stops growth of only directly injected EpCAM+ human tumor xenografts in immuno-incompetent mice (with i.v. human T cells). bit.ly/3Typnha
010
ACIR @acir-org.bsky.social · 17/09/2026
Xiang et al. developed a DC-directed dual pH-gated hybrid nanoparticle (HNP) that sequentially releases αCD47 peptides in the acidic TIME to enhance antigen acquisition and subsequently cGAMP under endosomal acidification to activate intracellular STING. bit.ly/3SMR1a3
000
ACIR @acir-org.bsky.social · 17/09/2026
Nishida et al. sought to prevent carcinogen (NMU)-induced mammary tumorigenesis in outbred Sprague-Dawley rats by targeting LALBA, a protein specifically expressed in luminal progenitor (LP) cells – the proposed cell-of-origin for breast cancer. bit.ly/3UZwj7q
000
ACIR @acir-org.bsky.social · 16/09/2026
Fine-tuning IL-2 delivery for cancer immunotherapy acir.org/weekly-dige...
011
ACIR @acir-org.bsky.social · 15/09/2026
Lin et al. developed a longitudinal scRNAseq atlas of 441 ICI-treated tumors from 241 patients across 10 cancer types, and identified 4 conserved TIME states. bit.ly/3SYlx0t
000
ACIR @acir-org.bsky.social · 14/09/2026
Groeneveldt et al. investigated mechanisms driving early-stage immune-related adverse events (irAEs) in patients with metastatic melanoma treated with combination ICB (anti-PD-1 and anti-CTLA-4). bit.ly/4A4rx8O  @aacrjournals.bsky.social
011
ACIR @acir-org.bsky.social · 11/09/2026
Swatler, Puccio, et al. used scRNsSeq and flow cytometry to define Treg subsets and analyze heterogeneity and TCR overlap across tissues from 9 tumor types. bit.ly/4yo9RTL
000
ACIR @acir-org.bsky.social · 11/09/2026
Liu et al. developed a genome-wide in vivo CRISPR screening platform using a T cell-attracting anti-CD3 scFv-expressing A375 tumor model and primary human T cells to identify in vivo regulators of intratumoral T cell abundance and effector function. bit.ly/4xhHzth
010
ACIR @acir-org.bsky.social · 10/09/2026
Arisato et al. found that the LLC-2B2 subclone of LLC was universally rejected in ICB-treated WT mice and was also rejected in 36% of ICB-treated Batf3-/- mice. In Batf3-/- mice, rejection was dependent on CD8+ T cells primed by alternative XCR1- APCs, which [...] bit.ly/3SF8l0B
000
ACIR @acir-org.bsky.social · 10/09/2026
Ex vivo-differentiated cDC1s offer superior tumor protection compared to monocyte-derived DCs used in DC vaccine trials. bit.ly/4xKS6y1
000
ACIR @acir-org.bsky.social · 09/09/2026
Enfortumab vedotin (Padcev) is approved for use in a number of clinical indications, and Olson and Liu et al. recently returned to the preclinical setting to untangle its mechanism acir.org/weekly-dige...
000
ACIR @acir-org.bsky.social · 08/09/2026
Sun et al. performed multi-omics analysis across nine stages of mouse HCC lung metastatic colonization, with supporting human data, to map the co-evolution of disseminated tumor cells (DTCs) and host immune niches. bit.ly/4i3Erxh
000
ACIR @acir-org.bsky.social · 07/09/2026
Ottensmeier and Delord et al. report a randomized phase I trial of adjuvant TG4050, an individualized MVA-vectored neoantigen vaccine encoding up to 30 predicted neoantigens, in high-risk resected HNSCC. bit.ly/4gF6TmM
000
ACIR @acir-org.bsky.social · 04/09/2026
Zhu and Yu et al. developed and characterized a scalable, feeder-free, high-yield platform that generated allogeneic NY-ESO-1-specific cytotoxic T (AlloESO-T) cells from cord blood-derived hematopoietic stem and progenitor cells. bit.ly/4qNx1QS
000
ACIR @acir-org.bsky.social · 04/09/2026
Zhu, Dann, et al. developed a transcriptome-wide and transcription factor genome-wide CRISPRi knockdown perturb-seq platform for human CD4+ T cells to comprehensively identify functional gene networks. bit.ly/46FO26g
000
ACIR @acir-org.bsky.social · 03/09/2026
Takacsi-Nagy et al. generated a library of synthetic T cell Transcription Factors through combinatorial assembly of AP-1 family TF subdomains. Expressed in CAR-T cells, certain sTFs improved CAR-T persistence/proliferation over natural TFs in a chronic stimulation assay. bit.ly/4qR03z5
000
ACIR @acir-org.bsky.social · 03/09/2026
Xu et al. identified optimal and reproducible culture and cytokine conditions to create universal, human iPSC-derived DCs lacking HLA (B2m/CTIIA KO) and with a CCR7+ migratory DC phenotype. bit.ly/4iIlGQ4
000
ACIR @acir-org.bsky.social · 02/09/2026
Role of AIRE in tumors acir.org/weekly-dige...
010
ACIR @acir-org.bsky.social · 25/08/2026
King-Peoples et al. assessed the Tn-glycosylated IIICS domain of fibronectin (Tn-FN) as an ECM-derived CAR target, and generated FDC6-BBζ CAR T cells using the FDC6 mAb. bit.ly/4x7ZXWd  @aacrjournals.bsky.social
011
ACIR @acir-org.bsky.social · 24/08/2026
Lu et al. profiled the cellular changes after KRAS(G12C) and MEK inhibition, and demonstrated that these treatments drove distinct neoplastic cell fates and immune responses in a CT26 KRASG12C tumor model. @aacrjournals.bsky.social @amgen.bsky.social bit.ly/4bSy8ZC
021
ACIR @acir-org.bsky.social · 21/08/2026
In a phase 1 trial, Li and Zhou et al. evaluated the EGFR-targeting, topoisomerase I inhibitor JS-1-carrying ADC SYS6010 in 236 patients with previously treated, advanced NSCLC (diverse subtypes and EGFR status). bit.ly/4giJiYH
001
ACIR @acir-org.bsky.social · 21/08/2026
Avraham and Barth et al. focused on optimizing the therapeutic potential of agonistic anti-GITR mAbs. Fc-engineered versions of human anti-GITR mAbs were evaluated in humanized FcγR mice. @yahelav.bsky.social @weizmann.ac.il @dahanlab.bsky.social bit.ly/4zsjS3N
000
ACIR @acir-org.bsky.social · 20/08/2026
In a phase 1 trial, Zhang, Chi, and Feng et al. treated 15 patients with B7-H3+ recurrent GBM with local delivery (intra-cerebroventricular or tumor cavity) of autologous B7-H3 CAR T cells. bit.ly/469UeTW
000
ACIR @acir-org.bsky.social · 20/08/2026
Li et al. performed a multiyear study, prospectively analyzing peripheral immune cells and plasma cytokines from 124 patients with advanced pan-solid tumors treated with anti-PD-L1 or anti-PD-1.  @aacrjournals.bsky.social bit.ly/4xa0kzK
021
ACIR @acir-org.bsky.social · 19/08/2026
New research shows that melanocytes utilize PD-L1 to protect themselves from immune-mediated clearance of UV-mutated cells acir.org/weekly-dige...
010
ACIR @acir-org.bsky.social · 18/08/2026
Kumar et al. characterized the transcriptome and proteome of the DC compartment in both pediatric and adult ALL, and demonstrated that DC maturation into functional lineages was disrupted. [...] @cityofhope.bsky.social bit.ly/4wsVP23
000
ACIR @acir-org.bsky.social · 17/08/2026
Kang and Han et al. developed PROTEXI, a vaccine platform comprising autologous DCs loaded with both tumor-specific CD8+ T and SARS-CoV-2 Spike protein CD4+ TH cell epitopes. In mouse tumor models, PROTEXI required both [...] bit.ly/4i9RgpA
000
ACIR @acir-org.bsky.social · 14/08/2026
Naara, Kochat, and Rao et al. compared the TIMEs of immunocompetent non-melanoma skin cancer (NMSC) patients and systemically immunosuppressed (IS) patients (organ transplant recipients or hematological cancer) who had reduced survival. bit.ly/4cCv2ZQ  @mdanderson.bsky.social
000
ACIR @acir-org.bsky.social · 14/08/2026
To overcome PDAC resistance to Kras* targeting using MRTX1133 or daraxonrasib, which enhances infiltration T cells, including various CD8+ T cell, CD4+ conventional T cell, and Treg phenotypes, Mahadevan et al. found [...]  @mdanderson.bsky.social bit.ly/3SxYFVr
000